- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04875624
Neurodevelopment of Hypoglycemic Neonates
Neurodevelopmental Outcome of Normoglycemic Versus Hypoglycemic Neonates at Risk for Hypoglycemia
Study Overview
Status
Intervention / Treatment
Detailed Description
Neonatal hypoglycemia is the most common metabolic problem in neonates and a preventable cause of brain injury in infancy. Key risk factors for neonatal hypoglycemia include being born preterm, small for gestational age (SGA), large for gestational age (LGA), and being an infant of a diabetic mother (IDM) (1). Approximately 30% of all neonates are considered at risk, of whom approximately 50% develop hypoglycemia (2). Neonatal hypoglycemia is tightly related to adverse neurodevelopmental and brain injury outcomes, particularly among preterm infants who are SGA (3). Screening is recommended for babies with known risk factors (4). Glucose is an essential molecule that supplies energy for brain consumption. Neurons and glial cells in the brain are sensitive to hypoglycemia. Neonatal hypoglycemia has been recognized as a cause of long-term severe neurologic and neurodevelopmental morbidity due to damage to these cells (5). Neonatal hypoglycemia is a common finding associated with brain injury, neurodevelopmental delay, visual impairment, and behavioral problems.
Management of hypoglycemia in the newborn period is highly variable among institutions, and recommendations from different professional societies vary. In 2011, the American Academy of Pediatrics (AAP) Committee on Fetus and Newborn published a clinical report suggesting management guidelines for late-preterm and term infants with associated risk factors, targeting infants of IDM, LGA and SGA neonates (2). Of note, AAP clinical report provides guidelines only for the initial 24 hours of life and recommends screening of IDM and LGA infants for 12 hours and screening of SGA and late preterm infants for 24 hours. Canadian Paediatric Society in their updated position statement recommends a similar screening algorithm based on risk factors, stressing the importance of adequate feeding in SGA and late preterm infants. The Pediatric Endocrine Society (PES) issued the recommendations for evaluation and management of persistent hypoglycemia in neonates, infants and children beyond the initial 24 hours of life. The 2011 AAP guidelines define neonatal hypoglycemia as blood glucose <47 mg/dL and recommend maintaining blood glucose >40 mg/dL in the first 4 hours and >45 mg/dl between hours 4-24 (6). The PES has an even stricter threshold of >50 mg/dL. The AAP guidance, however, applies only to the first 24 hours of life, and the PES strategy focuses on infants beyond 48 hours of life with persistent hypoglycemia (7).
Due to poor correlation between blood glucose concentrations, clinical manifestations and controversial treatment thresholds, it is difficult to define a safe blood glucose level. Several studies have analyzed the effects of various ranges of hypoglycemia on neurodevelopmental outcome. However, variable results regarding the effect of hypoglycemia on the neurodevelopmental outcome have been reported without any clear conclusion (5,8-12).
In this study investigators propose to prospectively conduct a neurodevelopmental evaluation of SGA and late preterm neonates who underwent risk-based screening for hypoglycemia at newborn nursery during the first 24 hours of life based on AAP hypoglycemia guidelines at 18 to 24 months of age. As per neonatal unit protocol (reflecting AAP guidelines), all neonates at risk of hypoglycemia (all preterm infants, term infants who are SGA or LGA and IDM) are routinely screened for hypoglycemia during the first 24 hours of life via bedside point of care glucose devices (see attached Weiler NICU hypoglycemia screening protocol).
Aims:
- To compare cognitive and motor development assessed with the Bayley-4 scoring system between the normoglycemic and hypoglycemic at-risk SGA/late preterm neonates
- To assess language development, social-emotional and adaptive behavior in the normoglycemic and hypoglycemic at-risk neonates
- To compare Bayley-4 scores between the cohort of neonates needing intravenous (IV) dextrose administration/neonatal intensive care admission to those with hypoglycemia managed in the newborn nursery as well as to those neonates who remained normoglycemic
Hypothesis:
The investigators hypothesize that SGA and late preterm hypoglycemic neonates admitted to newborn nursery will have inferior neurodevelopmental outcome at 18 to 24 months age when compared to SGA and late preterm infants with normoglycemia.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Thomas Havranek, MD
- Phone Number: 718-904-4105
- Email: thavrane@montefiore.org
Study Contact Backup
- Name: Palanikumar Balasundaram, MD
- Phone Number: 718-904-4105
- Email: pbalasunda@montefiore.org
Study Locations
-
-
New York
-
Bronx, New York, United States, 10461
- Recruiting
- Montefiore Medical Center, Weiler Hospital
-
Contact:
- Thomas Havranek, MD
- Phone Number: 718-904-4105
- Email: thavrane@montefiore.org
-
Contact:
- Palanikumar Balasundaram, MD
- Phone Number: 718-904-4105
- Email: pbalasunda@montefiore.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Born at 35 weeks or more of gestation
- Birth weight of 2000 g or more
- Indication for routine screening for hypoglycemia: late preterm infants (gestational age from 35 weeks 0 days to 36 weeks 6 days) and newborns who were SGA (birth weight below the 10th percentile on the 2013 Fenton curve).
Exclusion Criteria:
- Neonates with indication for hypoglycemia screening - screening not properly done or missing
- Unable to reach the subject for neurodevelopmental assessment
- Non-English speaking subjects
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Hypoglycemic neonates
Preterm or small for gestational age neonates at risk for hypoglycemia who were found to be hypoglycemic during the screening for hypoglycemia
|
Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) will be administered by one of the 2 blinded examiners who are unaware of neonatal glycemia status.
Bayley-4 examines Cognitive, Language, Motor, Social-Emotional and Adaptive Behavior domains of development and may require up to 120 minutes to complete.
|
Normoglycemic neonates
Preterm or small for gestational age neonates who were found to be normoglycemic during the screening for hypoglycemia
|
Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) will be administered by one of the 2 blinded examiners who are unaware of neonatal glycemia status.
Bayley-4 examines Cognitive, Language, Motor, Social-Emotional and Adaptive Behavior domains of development and may require up to 120 minutes to complete.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of cognitive development using Bayley-4 scoring system
Time Frame: 120 minutes
|
Compare cognitive development assessed with the Bayley-4 scoring system between the normoglycemic and hypoglycemic at-risk SGA/late preterm neonates
|
120 minutes
|
Comparison of motor development using Bayley-4 scoring system
Time Frame: 120 minutes
|
Assess motor development between the normoglycemic and hypoglycemic at-risk neonates
|
120 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of language development using Bayley-4 scoring system
Time Frame: 120 minutes
|
Compare language development using Bayley-4 scoring system between the normoglycemic and hypoglycemic at-risk neonates
|
120 minutes
|
Comparison of social-emotional behavior using Bayley-4 scoring system
Time Frame: 120 minutes
|
Comparison of social-emotional behavior using Bayley-4 scoring system between the normoglycemic and hypoglycemic at-risk neonates
|
120 minutes
|
Comparison of adaptive behavior using Bayley-4 scoring system
Time Frame: 120 minutes
|
Comparison of adaptive behavior using Bayley-4 scoring system between the normoglycemic and hypoglycemic at-risk neonates
|
120 minutes
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thomas Havranek, MD, Montefiore Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-13030
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurodevelopmental Disorders
-
University of Missouri-ColumbiaCompletedChildren With Neurodevelopmental DisordersUnited States
-
IRCCS Eugenio MedeaRecruitingNeurodevelopmental Disorder (Diagnosis)Italy
-
NeuroModulation Technique Research InstituteCompletedAutism | Neurodevelopmental DisorderUnited States
-
University of StrathclydeGöteborg University; University of Aberdeen; University of Glasgow; HarimataUnknownAutism Spectrum Disorder | Other Neurodevelopmental DisorderSweden, United Kingdom
-
National Institute of Mental Health (NIMH)RecruitingHealthy Children | Children With Neurodevelopmental Disorders | Children With Neuropsychiatric Disorders | Children With Behavioral SyndromesUnited States
-
Iama Therapeutics S.r.l.Recruiting
-
University of AlbertaAlberta Health servicesRecruitingNeurodevelopmental DisordersCanada
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingNeurodevelopmental Disorders
-
University of North Carolina, Chapel HillNational Center for Advancing Translational Sciences (NCATS); RTI InternationalCompletedNeurodevelopmental DisordersUnited States
-
ProbiSearch SLNot yet recruitingNeurodevelopmental Disorders
Clinical Trials on Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4)
-
Giancarlo NatalucciNot yet recruiting
-
Children's Hospital of PhiladelphiaUniversity of PennsylvaniaCompletedInfant DevelopmentUnited States
-
University Hospital, BrestRecruiting
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingAnesthesia | Infant Development | Anesthesia; Adverse EffectNetherlands
-
Emory UniversityNational Institute of Neurological Disorders and Stroke (NINDS)CompletedEpilepsy | Cognition Disorders | SeizureUnited States, United Kingdom